Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015

Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015–2020

Published:2023-10-03 Issue:12 Volume:62 Page:1784-1790
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Nørgaard Mette¹²^ORCID,Mailhac Aurélie¹,Fagerlund Karin³,Strunz-McKendry Torsten⁴,Agerbæk Mads²⁵,Jensen Jørgen Bjerggaard²⁶^ORCID

Affiliation:

1. Department of Clinical Epidemiology, Arhus University Hospital, Aarhus, Denmark

2. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

3. Astellas Pharma A/S - Nordic Operation, Copenhagen, Denmark

4. Astellas Pharma Europe Ltd, Addlestone, UK

5. Department of Oncology, Aarhus University Hospital, Aarhus, Denmark

6. Department of Urology, Aarhus University Hospital, Aarhus, Denmark

Funder

Astellas Pharma, Inc.

Publisher

Medical Journals Sweden AB

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2023.2263154

Reference23 articles.

1. NORDCAN: Cancer Incidence Mortality Prevalence and Survival in the Nordic Countries. Version 9.2 [Internet]. Association of the Nordic Cancer Registries. Cancer Registry of Norway. 2022 [cited 2003 May 15]. Available from: https://nordcan.iarc.fr/

2. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

3. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

4. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

5. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The usage of population and disease registries as pre-screening tools for clinical trials, a systematic review;Systematic Reviews;2024-04-23